AI Unlocks New Treatments for Diseases Once Thought Incurable

For decades, a diagnosis of amyotrophic lateral sclerosis (ALS) was a death sentence. Patients slowly lost control of their muscles, and no cure existed. But a new wave of artificial intelligence tools is changing that narrative.

Researchers are now using AI to find new uses for existing drugs, slashing the time and cost of developing treatments for conditions once considered hopeless. The results, while early, are already turning heads in the medical community.

From years to months: How AI speeds up drug discovery

Traditional drug development is a slog. It can take over a decade and billions of rupees to bring a single drug to market. For rare or complex diseases, the economics often don't add up.

AI changes this by sifting through massive datasets — genetic profiles, protein structures, clinical trial records — in hours instead of years. Machine learning models can predict how a molecule will behave in the human body, flagging promising candidates for further testing.

One AI system, trained on thousands of failed drug compounds, recently identified a combination of two existing medications that slowed disease progression in a small group of ALS patients. The discovery would have taken researchers years using conventional methods.

A personal victory: The ALS patient who improved

In one case reported by researchers, a patient with advanced ALS who had lost the ability to speak began to regain some motor function after being placed on an AI-recommended drug regimen. The improvement was modest but meaningful — the patient could once again move their fingers and communicate using a tablet.

Doctors caution that this is a single case and not a clinical trial. But the result has electrified the field. "It's not a cure, but it's a sign that we're on the right track," one researcher involved in the study told the BBC.

The AI had identified the drug combination by analysing the patient's unique genetic markers and matching them with molecular profiles of thousands of approved medicines. This personalised approach is at the heart of the AI revolution in medicine.

Beyond ALS: Rare cancers and hidden cures

ALS is not the only disease benefiting from this approach. The same AI tools are being deployed against rare cancers, autoimmune disorders, and neurodegenerative diseases.

In one project, an AI model predicted that a cheap, widely available arthritis drug could be effective against a form of lung cancer that affects non-smokers. Clinical trials are now underway in India and the United Kingdom.

The key advantage is repurposing. Since these drugs have already passed safety tests, they can be fast-tracked to patients. This is especially critical for diseases where no treatment exists at all.

Indian researchers are also getting in on the act. Several labs in Bengaluru and Hyderabad are using AI to screen traditional Ayurvedic compounds against modern disease targets, hoping to find new uses for ancient remedies.

Challenges remain: Data, cost, and regulation

Despite the promise, hurdles remain. AI models are only as good as the data they are trained on. Many rare diseases lack high-quality datasets, which can lead to biased or unreliable predictions.

Regulatory agencies are also playing catch-up. The Drugs Controller General of India and the US Food and Drug Administration are still figuring out how to evaluate AI-derived treatment recommendations. No formal guidelines exist yet for approving drugs based solely on computational predictions.

Cost is another factor. While AI reduces research time, the initial investment in computing power and talent is steep. Smaller labs in India may struggle to compete with well-funded Western institutions.

Still, the trajectory is clear. AI is not replacing doctors or researchers — it is giving them a powerful new tool. The next few years will determine whether these early wins can be scaled into real, lasting treatments.

What to watch: Several large-scale clinical trials for AI-identified drug repurposing are expected to begin in late 2026. If they succeed, the way we treat incurable diseases could change forever.